BMS-1166

BMS-1166 is a potent PD-1/PD-L1 immune checkpoint inhibitor. BMS-1166 induces dimerization of PD-L1 and blocks its interaction with PD-1, with an IC50 of 1.4 nM. BMS-1166 antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation[1][2].

Product Specifications

CAS Number

[1818314-88-3]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

PD-1/PD-L1

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/BMS-1166.html

Purity

99.64

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C(O)[C@@H]1N(CC2=CC(Cl)=C(OCC3=CC=CC(C4=CC=C(OCCO5)C5=C4)=C3C)C=C2OCC6=CC=CC(C#N)=C6)C[C@H](O)C1

Molecular Formula

C36H33ClN2O7

Molecular Weight

641.11

Precautions

H302, H315, H319, H335

References & Citations

[1]Guzik K, et al. Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1. J Med Chem. 2017 Jul 13;60 (13) :5857-5867.|[2]Skalniak L, et al. Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells. Oncotarget. 2017 Aug 7;8 (42) :72167-72181.